http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Particle Growth in Oxalate Process I
Park, Zee-Hoon,Shin, Hyo-Soon,Lee, Byung-Kyo The Korean Ceramic Society 1996 The Korean journal of ceramics Vol.2 No.2
Barium titanyl oxalates, strontium titanyl oxalates and calcium zirconyl oxalates were prepared with variation of solution concentration and method of adding mixed metal ion solution into oxalic acid. Then they were aged in distilled water, ethanol or methanol, respectively. Barium titanyl oxalates and calcium zironyl oxalates were grown in water and strontium titanyl oxalates were groun in both water and methanol. They were supposed to be grown through the solutionl and reprecipitation mechanism. Nonuniform dispersion of particles in liquid phase is thought to cause abnormal particle growth.
Yee Zee Bae,Jae Hyuk Jung,Chang Hoon Moon,Seong Hyun Kim,Hyuk Chan Kwon,Jae Seok Kim,Hyo Jin Kim 대한암학회 2002 Cancer Research and Treatment Vol.34 No.3
Purpose: There are few therapeutic options in patientswith colorectal cancer that have progressed or recurredfollowing 5-fluorouracil (5-FU) based therapy. We evaluatedthe efficacy and toxicity of oxaliplatin, 5-FU, leucovorin(Mayo clinic regimen) in 5-FU pretreated advancedcolorectal cancer patients.Materials and Methods: Twenty-eight patients wereenrolled in this study between January 1999 and May2001. Patients were treated with oxaliplatin 150 mg/m2 onday 1 as a 2-hr infusion and 5-FU 425 mg/m2, leucovorin20 mg/m2, bolus for 5 days. Treatment courses wererepeated in 4-week intervals.Results: The objective response rate was 25% for 28assessable patients, all cases registered a partial response.Eleven patients (39%) demonstrated stable disease,and ten (36%) progressed. The median responseduration was 5.5 months, and the median time to progressionwas 6.3 months. The median overall survivaltime was 13.5 months from the start of the chemotherapy.From the 120 cycles analyzed, grade 3,4 hematologictoxicities included neutropenia: 1.6%, and thrombocytopenia:1.6%. The frequent grade 3.4 non-hematologicadverse reactions were nausea/vomiting (25.0%), diarrhea(14.3%), stomititis (3.6%), and neuropathy (3.6%). Therewere no treatment-related deaths.Conclusion: This phase II study had relatively highertoxicity than previous studies, and did not show anincreased significant response rate. These high levels oftoxicity suggest that the study treatment combination ofoxaliplatin with a full dose Mayo clinic regimen arm is nofeasible. Therefore, this regimen will be discontinued anda safer regimen will be adopted. (Cancer Res Treat. 2002;34:218-222)
Parametric Study on Design Factors of the Shutdown Cooling Heat Exchanger Using the Taguchi Method
Kim Seong Hoon,Ryu Seung Yeob,Choi Byung Seon,Yoon Juhyeon,Bae Yoon Yeong,Zee Sung Kyun Korean Nuclear Society 2003 Nuclear Engineering and Technology Vol.35 No.3
The Taguchi method was applied to investigate the effect of design factors on the performance of the shutdown cooling heat exchanger in the SMART-P. This method provided the simulation matrix for the KDESCENT program and an efficient tool for analyzing the simulation results. Levels of the design factors were selected by the effectiveness-NTU method. From 18 runs with the KDESCENT program, it was found that the performance of the system was greatly influenced by the inlet temperature at the shell side and the mass flow rate of the reactor coolant at the tube side. After applying the Taguchi method, we identified the important design factor that should be controlled and designed carefully. This method provides an efficient way to estimate the influence of each design factor on a system performance.
흰쥐의 좌골신경에 1% 페놀용액을 주입한 실험용 신경병변성 동통모델의 개발
이기훈,이지인,김영은,이양수,김풍택,김명남 경북대학교 의학연구소 2000 경북대학교병원의학연구소논문집 Vol.4 No.1
Development of Neuropathic Pain Model with 1% Phenol Injection in Rat Sciatic Nerve Objective: The purpose of this study is to develop a new neuropathic pain model in the rat. Method: Each male adult rat was anesthetized and the sciatic nerve was exposed. Each exposed nerve was injected with 0.03 cc of 1% phenol solution. Normal saline 0.03 cc was injected to the placebo group. Rats were tested for the presence of mechanical allodynia by von Frey hair. Spontaneous pain behavior (paw shaking, paw elevation) was examined for 5 minutes in the cage. Results: Phenol injected group developed allodynia after the second post-injection day for up to 1 month. Allodynia was also observed in the contralateral lags of phenol injected group. The control group did not develop allodynia. Spontaneous pain behavior was not observed in either group. Conclusion: Neuropathic pain model was developed by 1 % phenol solution injection to the rat sciatic nerve. This study suggests an easier method for making the neuropathic pain model.
황성일,Bum-Suk Lee,Zee-A Han,Hye-Jin Lee,Sang-Hoon Han,Myeong-Ok Kim 대한재활의학회 2016 Annals of Rehabilitation Medicine Vol.40 No.4
Objective To analyze the factors related to urinary tract infection (UTI) occurrence after an urodynamic study (UDS) in patients with spinal cord injury (SCI).Methods We retrospectively investigated the medical records of 387 patients with SCI who underwent UDS with prophylactic antibiotic therapy between January 2012 and December 2012. Among them, 140 patients met the inclusion criteria and were divided into two groups, UTI and non-UTI. We statistically analyzed the following factors between the two groups: age, sex, level of injury, SCI duration, spinal cord independence measure, non-steroidal anti-inflammatory drug use, diabetes mellitus, the American Spinal Injury Association impairment scale (AIS), lower extremity spasticity, a history of UTI within the past 4 weeks prior to the UDS, symptoms and signs of neurogenic bladder, urination methods, symptoms during the UDS and UDS results. Results Among the 140 study participants, the UTI group comprised 12 patients and the non-UTI group comprised 128 patients. On univariate analysis, a history of UTI within the past 4 weeks prior to the UDS was significant and previous autonomic dysreflexia before the UDS showed a greater tendency to influence the UTI group. Multivariable logistic regression analysis using these two variables showed that the former variable was significantly associated with UTI and the latter variable was not significantly associated with UTI.Conclusion In patients with SCI, a history of UTI within the past 4 weeks prior to the UDS was a risk factor for UTI after the UDS accompanied by prophylactic antibiotic therapy. Therefore, more careful pre-treatment should be considered when these patients undergo a UDS.
Je Hyuk Chung,Yee Zee Bae,Sung Hyun Kim,Chang Hoon Moon,Jun Young Chung,Hyuk Chan Kwon,Jae Seok Kim,Hyo Jin Kim 대한암학회 2002 Cancer Research and Treatment Vol.34 No.5
Purpose: There is no effective treatment for patientswith advanced gastric cancer having failed to respond tofirst line chemotherapy. The aim of this study was toevaluate the therapeutic activity, and safety, of a FEPregimen in patients with a recurrence of, or metastatic,gastric cancer that had been unresponsive to primarychemotherapy.Materials and Methods: Recurred or metastatic gastriccancer patients that did not respond to a 5-fluorouracilbased regimen were entered into this trial. The patientswere treated with FEP (5-FU, etoposide and cisplatin) assalvage chemotherapy. The treatment regimen was 5-FU(900 mg/m2/day) by continuous infusion for 3 days, etoposide(90 mg/m2/day) on days 1, 2 and 3, and cisplatin(60 mg/m2/day) on day 2. This treatment was repeatedevery 3 weeks.Results: Between December 1997 and October 2001, 28patients were enrolled to the study. The response rate was32.1% (95% CI 15.5~57.8%). The median times to progressionand survival duration were 23~33 weeks, respectively.Among a total of 187 cycles of chemotherapy, the grade3 and 4 hematological toxicities were leukopenia (6.4%),thrombocytopenia (1.6%), and grade 3 non-hematologicalside effects of nausea/vomiting (17.9%).Conclusion: FEP combination chemotherapy seems tobe an effective treatment regimen for gastric cancer assalvage chemotherapy. To confirm these results, largescale of clinical trials will be required. (Cancer Res Treat. 2002;34:382-387)